Pediatrix Medical Group Reaffirms 2026 Outlook With Stable Payor Mix and Adjusted EBITDA Guidance of $280M–$300M
Pediatrix Medical Group Issues Second Quarter 2026 Business ...
Sign in to continue:
Pediatrix Medical Group Issues Second Quarter 2026 Business ...
Axsome Therapeutics: FDA Accepts NDA for AXS-12 in Narcoleps...
Hycroft Mining Appoints Michael Deal as COO – Key Developmen...
Entegris Declares Quarterly Cash Dividend – Investor Update ...
Worthington Steel Announces Start of Delisting Tender Offer ...
Senti Biosciences Holdings Announces Strategic Spin-Off and ...
Johnson & Johnson Reports Strong Q2 2026 Results and Raises ...
Morgan Stanley Q2 2026 Earnings: Record Revenues, Robust Pro...
CH Offshore Ltd.: Profit Guidance and Financial Outlook for ...
Profound Medical Corp. Form 8-K – Investor Report Prof...